CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM)
HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that Sandra Silberman, M.D., Ph.D., Chief Medical Officer of CNS Pharmaceuticals, will present at the Lenox Hill Hospital, Department of Neurosurgery's Brain Tumor Biotech Summit being held on June 5, 2025 in New York, NY.
Details of the presentation are as follows:
Title: The Future and Promise of TPI 287- A Brain Penetrating Taxane with Documented Evidence of Efficacy Against Glioblastoma
Date and Time: Thursday, June 5, 2025 at 9:30 AM ET
As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) and docetaxel, in which it stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. While most taxanes are substrates for multi-drug resistant transporters, which maintain the blood brain barrier (BBB), TPI 287's clinical data suggest it has the potential to cross the BBB and treat CNS tumors. In a Phase 1 trial treating glioblastoma patients with TPI 287 in combination with bevacizumab (Avastin®), the efficacy data included 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients.
TPI 287 has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of gliomas, pediatric neuroblastoma, and progressive supranuclear palsy.
The 2025 Brain Tumor Biotech Summit brings together innovators in neuroscience and oncology with investors in the field of biotechnology and healthcare life science. The Conference's goal is to foster and encourage collaboration among our neuroscience colleagues and the biotechnology community to accelerate the development of new, life-saving therapies for patients with brain tumors and other Central Nervous System diseases.
For more information about the 2025 Brain Tumor Biotech Summit, please visit the event website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. . These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. 'Risk Factors' in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ('SEC') and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT:
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
17 minutes ago
- Associated Press
Attorneys in NCAA antitrust case to share $475M in fees, with potential to reach $725M
The attorneys who shepherded the blockbuster antitrust lawsuit to fruition for hundreds of thousands of college athletes will share in just over $475 million in fees, and the figure could rise to more than $725 million over the next 10 years. The request for plaintiff legal fees in the House vs. NCAA case, outlined in a December court filing and approved Friday night, struck experts in class-action litigation as reasonable. Co-lead counsels Steve Berman and Jeffrey Kessler asked for $475.2 million, or 18.3% of the cash common funds of $2.596 billion. They also asked for an additional $250 million, for a total of $725.2 million, based on a widely accepted estimate of an additional $20 billion in direct benefits to athletes over the 10-year settlement term. That would be 3.2% of what would then be a $22.596 billion settlement. 'Class Counsel have represented classes of student-athletes in multiple litigations challenging NCAA restraints on student-athlete compensation, and they have achieved extraordinary results. Class Counsel's representation of the settlement class members here is no exception,' U.S. District Judge Claudia Wilken wrote. University of Buffalo law professor Christine Bartholomew, who researched about 1,300 antitrust class-action settlements from 2005-22 for a book she authored, told The Associated Press the request for attorneys' fees could have been considered a bit low given the difficulty of the case, which dates back five years. She said it is not uncommon for plaintiffs' attorneys to be granted as much as 30% of the common funds. Attorneys' fees generally are calculated by multiplying an hourly rate by the number of hours spent working on a case. In class-action lawsuits, though, plaintiffs' attorneys work on a contingency basis, meaning they get paid at the end of the case only if the class wins a financial settlement. 'Initially, you look at it and think this is a big number,' Bartholomew said. 'When you look at how contingency litigation works generally, and then you think about how this fits into the class-action landscape, this is not a particularly unusual request.' The original lawsuit was filed in June 2020 and it took until November 2023 for Wilken to grant class certification, meaning she thought the case had enough merit to proceed. Elon University law professor Catherine Dunham said gaining class certification is challenging in any case, but especially a complicated one like this. 'If a law firm takes on a case like this where you have thousands of plaintiffs and how many depositions and documents, what that means is the law firm can't do other work while they're working on the case and they are taking on the risk they won't get paid,' Dunham said. 'If the case doesn't certify as a class, they won't get paid.' In the request for fees, the firm of Hagens Berman said it had dedicated 33,952 staff hours to the case through mid-December 2024. Berman, whose rate is $1,350 per hour, tallied 1,116.5 hours. Kessler, of Winston & Strawn, said he worked 1,624 hours on the case at a rate of $1,980 per hour. The case was exhaustive. Hundreds of thousands of documents totaling millions of pages were produced by the defendants — the NCAA, ACC, Big Ten, Big 12, Pac-12 and SEC — as part of the discovery process. Berman and Kessler wrote the 'plaintiffs had to litigate against six well-resourced defendants and their high-powered law firms who fought every battle tooth and nail. To fend off these efforts, counsel conducted extensive written discovery and depositions, and submitted voluminous expert submissions and lengthy briefing. In addition, class counsel also had to bear the risk of perpetual legislative efforts to kill these cases.' Antitrust class-action cases are handled by the federal court system and have been harder to win since 2005, when the U.S. Class Action Fairness Act was passed, according to Bartholomew. 'Defendants bring motion after motion and there's more of a pro-defendant viewpoint in federal court than there had been in state court,' she said. 'As a result, you would not be surprised that courts, when cases do get through to fruition, are pretty supportive of applications for attorneys' fees because there's great risk that comes from bringing these cases fiscally for the firms who, if the case gets tossed early, never gets compensated for the work they've done.' ___ AP college sports:
Washington Post
27 minutes ago
- Washington Post
Vance says Musk making a 'huge mistake' in going after Trump but also tries to downplay the attacks
BRIDGEWATER, N.J. — Vice President JD Vance said Elon Musk was making a 'huge mistake' going after President Donald Trump in a storm of bitter and inflammatory social media posts after a falling out between the two men . But the vice president, in an interview released Friday after the very public blow up between the world's richest man and arguably the world's most powerful, also tried to downplay Musk's blistering attacks as an 'emotional guy' who got frustrated.
Fox News
30 minutes ago
- Fox News
Artificial Intelligence Newsletter
This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.
